TABLE 3.
HR HPV positivity of the Xpert HPV versus a clinically validated comparator testa
| hc2 or GP5+/6+ EIA result | Xpert HPV result (no.) |
Total | |
|---|---|---|---|
| + | − | ||
| CIN2+, age ≥30 yr | |||
| + | 62 | 2 | 64 |
| − | 1 | 3 | 4 |
| Total | 63 | 5 | 68 |
| <CIN2+, age ≥30 yr | |||
| + | 300 | 100 | 400 |
| − | 82 | 2,724 | 2,806 |
| Total | 382 | 2,824 | 3,206 |
| CIN2+, all ages | |||
| + | 171 | 2 | 173 |
| − | 2 | 5 | 7 |
| Total | 173 | 7 | 180 |
| <CIN2, all ages | |||
| + | 611 | 130 | 741 |
| − | 125 | 3,305 | 3,430 |
| Total | 736 | 3,435 | 4,171 |
a
Aggregated data are from VALGENT-2 and Cuzick et al. (7). Data are stratified according to the presence or absence of underlying disease and separately for women of all ages and women aged ≥30 years.